This R21 grant from the National Cancer Institute (NCI) and National Institutes of Health (NIH) is for exploratory research projects focusing on the initial application of emerging analytical technologies in cancer research. It seeks technologies that have passed early development but need evaluation for their intended use as laboratory or clinical tools. The grant aims to accelerate research in cancer biology, treatment, diagnosis, prevention, control, epidemiology, and health disparities. Projects should demonstrate high potential impact and can carry technical risk, without requiring preliminary data, but must include quantitative milestones. This funding opportunity is part of NCI’s Innovative Molecular Analysis Technologies (IMAT) Program, offering approximately $2.25 million for up to seven awards over a maximum two-year period, with direct costs capped at $275,000.
Opportunity ID: 49991
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-10-003 |
| Funding Opportunity Title: | Application and Early Stage Development of Emerging Technologies in Cancer Research (R21) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 26, 2009 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Sep 30, 2010 |
| Current Closing Date for Applications: | Sep 30, 2010 |
| Archive Date: | Oct 31, 2010 |
| Estimated Total Program Funding: | $2,250,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education Small businesses Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications that propose exploratory research projects on the initial application of emerging analytical technologies as laboratory or clinical tools. An emerging technology is defined as one that has passed the initial developmental stage, but has not yet been evaluated within the context of its intended use. Projects proposed in response to this FOA should have the potential to produce a major impact in a broad area of cancer-relevant research. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R21 applications that have high potential impact and allows for an element of technical risk; preliminary data are not required. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-10-004, that solicits applications under the NIH Application R33 grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $2,250,000 to this FOA in fiscal year 2010 to fund up to 7 applications in response to this FOA. Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-10-003.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| ADOBE-FORMS-B-REPOSTED | Use for submissions intended for due dates of January 25, 2010 and beyond | PKG00015948 | Jan 23, 2010 | Sep 30, 2010 | View |
Package 1
Mandatory forms
49991 RR_SF424_1_2-1.2.pdf
49991 PerformanceSite_1_3-1.3.pdf
49991 RR_OtherProjectInfo_1_2-1.2.pdf
49991 RR_KeyPersonExpanded_1_2-1.2.pdf
49991 PHS398_CoverPageSupplement_1_4-1.4.pdf
49991 PHS398_ResearchPlan_1_3-1.3.pdf
49991 PHS398_Checklist_1_3-1.3.pdf
Optional forms
49991 PHS_CoverLetter_1_2-1.2.pdf
49991 PHS398_ModularBudget-1.1.pdf
49991 RR_Budget-1.1.pdf
49991 RR_SubawardBudget-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
